NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat

Behavioural Brain Research

Volumn 210, Issue 2, 2010, Pages 221-228

  Guan, Jian ^a   Zhang, Rong ^a   Dale Gandar, Linden ^a   Hodgkinson, Steve ^a   Vickers, Mark H ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Diketopiperazine; M2AChR and rats; Scopolamine; Spatial memory; Water maze

Indexed keywords

CHOLINE ACETYLTRANSFERASE; CYCLO GLYCYL 2 ALLYLPROLINE; NEUROPROTECTIVE AGENT; NNZ 2591; PIPERAZINEDIONE; SCOPOLAMINE; SODIUM CHLORIDE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; WATER;

ACUTE DISEASE; ADULT ANIMAL; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; ENZYME REGULATION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MAZE TEST; MEMORY CONSOLIDATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPONSE TIME; SPATIAL MEMORY; UPREGULATION; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CHOLINE O-ACETYLTRANSFERASE; DIKETOPIPERAZINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUTAMATE DECARBOXYLASE; HIPPOCAMPUS; LOCOMOTION; MALE; MAZE LEARNING; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; REACTION TIME; RECEPTOR, MUSCARINIC M2; RECEPTORS, AMPA; SCOPOLAMINE; SYNAPTOPHYSIN; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 77952321367     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.02.039     Document Type: Article

References (38)

1. Samonina G., Ashmarin I., Lyapina L. Glyproline peptide family: review on bioactivity and possible origins. Pathophysiology 2002, 8(4):229-234.
2. Gudasheva T.A., Boyko S.S., Ostrovskaya R.U., Voronina T.A., Akparov V.K., Trofimov S.S., et al. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-l-prolylglycine. Eur J Drug Metab Pharmacokinet 1997, 22(3):245-252.
3. Faden A.I., Knoblach S.M., Cernak I., Fan L., Vink R., Araldi G.L., et al. Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J Cereb Blood Flow Metab 2003, 23(3):342-354.
4. Faden A.I., Movsesyan V.A., Knoblach S.M., Ahmed F., Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology 2005, 49(3):410-424.
5. Faden A.I., Knoblach S.M., Movsesyan V.A., Cernak I. Novel small peptides with neuroprotective and nootropic properties. J Alzheimers Dis 2004, 6(6 Suppl):S93-S97.
6. Guan J., Mathai S., Harris A.P., Wen J.Y., Zhang R., Brimble M.A., et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor funcion following hypoxia-ischemia in adult rats. Neuropharmacology 2007, 53:749-762.
7. Krishnamurthi R., Mathai S., Kim H., Zhang R., Guan J. A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA induced motor deficit in rats. Br J Pharmacol 2008, 156(4):662-672.
8. Rosenzweig E.S., Barnes C.A. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol 2003, 69(3):143-179.
9. Driscoll I., Sutherland R.J. The aging hippocampus: navigating between rat and human experiments. Rev Neurosci 2005, 16(2):87-121.
10. D'Hooge R., De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001, 36(1):60-90.
11. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain Res Rev 2003, 41(2-3):268-287.
12. Bymaster F.P., Heath I., Hendrix J.C., Shannon H.E. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 1993, 267(1):16-24.
13. Savage U.C., Faust W.B., Lambert P., Moerschbaecher J.M. Effects of scopolamine on learning and memory in monkeys. Psychopharmacology 1996, 123(1):9-14.
14. Drachman D.A., Leavitt J. Human memory and the cholinergic system. A relationship to aging?. Arch Neurol 1974, 30(2):113-121.
15. Buccafusco J.J., Terry A.V., Webster S.J., Martin D., Hohnadel E.J., Bouchard K.A., et al. The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology (Berl) 2008, 199(3):481-494.
16. Mitchell E.S., Hoplight B.J., Lear S.P., Neumaier J.F. BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism. Neuropharmacology 2006, 50(4):412-420.
17. Guan J., Thomas G.B., Lin H., Mathai S., Bachelor D.C., George S., et al. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology 2004, 47(6):892-903.
18. Paxinos G., Watson C.D. The rat brain stereotaxic coordinations 1982, Academic press, New York.
19. Niittykoski M., Hakkarainen V., Puumala T., Lappalainen R., Ruotsalainen S., Haapalinna A., et al. Systemic administration of atipamezole, an alpha 2-antagonist, can reduce scopolamine-induced hyperactivity in rats. Behav Pharmacol 1997, 8(5):465-470.
20. Lima J.A., Costa R.S., Epifanio R.A., Castro N.G., Rocha M.S., Pinto A.C., et al. Geissospermum vellosii stembark: anticholinesterase activity and improvement of scopolamine-induced memory deficits n-3 phosphatidylserine attenuated scopolamine-induced amnesia in middle-aged rats. Pharmacol Biochem Behav 2009, 92(3):508-513.
21. Zhang L., Xu J.Q., Rong S., Xie B.J., Sun Z.D., Zhang Y.J., et al. The mixture of procyanidins extracted from the lotus seed pod and bilobalide ameliorates scopolamine-induced memory impairment in mice. Neurosci Bull 2009, 25(4):203-208.
22. Iversen S.D. Behavioural evaluation of cholinergic drugs. Life Sci 1997, 60(13-14):1145-1152.
23. Walter R., Hoffman P.L., Flexner J.B., Flexner L.B. Neurohypophyseal hormones, analogs, and fragments: their effect on puromycin induced amnesia. Proc Natl Acad Sci USA 1975, 72(10):4180-4184.
24. Gudasheva T.A., Boyko S.S., Akparov V.K., Ostrovskaya R.U., Skoldinov S.P., Rozantsev G.G., et al. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Lett 1996, 391(1-2):149-152.
25. Ostrovskaya R.U., Gruden M.A., Bobkova N.A., Sewell R.D., Gudasheva T.A., Samokhin A.N., et al. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. J Psychopharmacol 2007, 21(6):611-619.
26. Eglen R.M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006, 26(3):219-233.
27. Mrzljak L., Levey A.I., Goldman-Rakic P.S. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 1993, 90(11):5194-5198.
28. Alcantara A.A., Mrzljak L., Jakab R.L., Levey A.I., Hersch S.M., Goldman-Rakic P.S. Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways. J Comp Neurol 2001, 434(4):445-460.
29. Rowe W.B., O'Donnell J.P., Pearson D., Rose G.M., Meaney M.J., Quirion R., et al. Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats. Behav Brain Res 2003, 145(1-2):171-178.
30. Das S., Bhargava H.N. Lack of interaction between thyrotropin releasing hormone and its analogs with 3H-quinuclidinyl benzilate recognition sites in the rat striatum. Neuropharmacology 1985, 24(7):681-683.
31. Guan J., Waldvogel H.J., Faull R.L., Gluckman P.D., Williams C.E. The effects of the N-terminal tripeptide of insulin-like growth factor- 1, glycine-proline-glutamate in different regions following hypoxic- ischemic brain injury in adult rats. Neuroscience 1999, 89(3):649-659.
32. Bellucci A., Luccarini I., Scali C., Prosperi C., Giovannini M.G., Pepeu G., et al. Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis 2006, 23(2):260-272.
33. Jacobson J., Zhang R., Elliffe D., Chen K., Mathai S., McCarthy D., et al. Co-relation of cellular changes and spatial memory during aging in rats. Exp Gerontol 2008, 43:928-938.
34. Kessels H.W., Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron 2009, 61(3):340-350.
35. Santos S.D., Carvalho A.L., Caldeira M.V., Duarte C.B. Regulation of AMPA receptors and synaptic plasticity. Neuroscience 2009, 158(1):105-125.
36. Bredt D.S., Nicoll R.A. AMPA receptor trafficking at excitatory synapses. Neuron 2003, 40(2):361-379.
37. Van der Zee E.A., Luiten P.G. GABAergic neurons of the rat dorsal hippocampus express muscarinic acetylcholine receptors. Brain Res Bull 1993, 32(6):601-609.
38. Bolam J.P., Bennett BD Microcircuitry of the neostriatum microcircuitry of the neostriatum 1995, 1-19. R.G. Landes Company, Austin. M.A. Ariano, D.J. Surmeier (Eds.).